Michel Sadelain

USPTO Granted Patents = 34 (Patent Applications = 41)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 13 (Patent Applications = 43)

Average Co-Inventor Count = 2.8

ph-index = 8

Forward Citations = 785(Granted Patents)

Company Filing History:

30 out of 559

Memorial Sloan Kettering Cancer Center

patents

5 out of 512

Sloan-kettering Institute for Cancer Research

patents

5 out of 3,435

National Institutes of Health, a Component of the US Dept. of Health & Human Services

patents

4. 1 out of 20

Memorial Hospital for Cancer and Allied Diseases

patents

5. 1 out of 850

Millennium Pharmaceuticals Limited

patents

6. 1 out of 2,099

University of Washington

patents

where one patent can have more than one assignee

Years Active: 2002-2025

Loading Chart...

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12345712 - Cancer antigen targets and uses thereof (2025-07-01),

2. 12331129 - Chimeric receptors targeting ADGRE2 and/or CLEC12A and uses thereof (2025-06-17),

3. 12275802 - Compositions and methods for immunotherapy (2025-04-14),

4. 12263220 - Compositions and methods for immunotherapy (2025-04-01),

5. 12259390 - Cancer antigen targets and uses thereof (2025-03-25),

6. 12139524 - Immune cell compositions and methods of use (2024-11-12),

7. 12036244 - Cells comprising non-HLA restricted T cell receptors (2024-07-16),

8. 12018077 - Methods of treatments using antigen-binding proteins targeting CD56 (2024-06-25),

9. 11932690 - Enhanced chimeric antigen receptors and uses thereof (2024-03-19),

10. 11753654 - Globin gene therapy for treating hemoglobinopathies (2023-09-12),

11. 11717579 - Globin gene therapy for treating hemoglobinopathies (2023-08-08),

12. 11712469 - Compositions and methods for immunotherapy (2023-08-01),

13. 11702472 - Method of reducing mesothelin-expressing tumor burden by administration of T cells comprising mesothelin-targeted chimeric antigen receptors (2023-07-18),

14. 11267901 - Compositions and methods for immunotherapy (2022-03-08),

15. 11242375 - Immune cell compositions and methods of use (2022-02-08),

Title: The Innovative Journey of Inventor Michel Sadelain

Introduction: Michel Sadelain is a renowned inventor based in New York, NY (US) known for his groundbreaking contributions to the field of biotechnology and genetic engineering.

Latest Patents: Michel Sadelain holds several patents in the areas of gene therapy, immunotherapy, and cancer treatment, showcasing his commitment to advancing medical science through innovation.

Career Highlights: With a distinguished career spanning over two decades, Michel Sadelain has made significant strides in developing novel therapies for various diseases, particularly focusing on harnessing the power of the immune system to combat cancer.

Collaborations: Throughout his career, Michel Sadelain has collaborated with leading research institutions, pharmaceutical companies, and academic partners to further his research and bring his inventions to the forefront of medical advancements.

Conclusion: Michel Sadelain's relentless pursuit of innovation and his dedication to improving patient outcomes have solidified his position as a pioneering inventor in the field of biotechnology, leaving a lasting impact on the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.